TLSI · TriSalus Life Sciences, Inc.
$4.27
+0.03 (+0.71%)
At close · Jul 23
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy.”View the 10-Q filed May 12, 2026
Market Cap
$262.25M
Shares
61.42M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO | $4,823,349 |
| David B. Patience | CFO | $3,443,628 |
| Richard Marshak | Chief Commercial Officer | $1,556,000 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO | $4,136,595 |
| Sean Murphy | CFO | $2,312,533 |
| Jodi Devlin | Chief of Clinical Operations | $1,383,741 |
| Richard Marshak | Chief Commercial Officer | $1,365,569 |
| David B. Patience | CFO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mary Szela | CEO | $2,692,830 |
| Steven Katz | Chief Medical Officer | $1,613,005 |
| Sean Murphy | CFO | $1,393,246 |
| Jodi Devlin | Chief of Clinical Operations | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven Katz | Chief Medical Officer | $799,146 |
| Mary Szela | CEO | $641,901 |
| Sean Murphy | CFO | $329,597 |
Key facts
CIK
1826667
CUSIP
89680M101
13F (30d)
10 filings
10 filers
Visit website
Investor relations